



doping free

RE-CROSS[®]

Cross-Linked Sodium Hyaluronate for Intra-Articular Injections

by
Reviscon

Motion is life



POWERED BY
HXL
HYBRID **XLINK**
TECHNOLOGY™

VSY Biotechnology

We inspire!

With **VSY Biotechnology**, you can rely on over 15 years of experience in science driven development, manufacturing, and marketing of innovative medical products. Our orthopedic portfolio covers a wide and unique range of biotechnologically produced intra-articular hyaluronic acid injection products for the treatment of osteoarthritis; all of them produced under the highest industry standards, certified across the globe and clinically proven to be safe, effective and well tolerated by patients around the globe!

Re-Cross by Reviscon® - A new benchmark in OA treatment!

With **Re-Cross by Reviscon®**, powered by our unique and proprietary **HXL HYBRID XLink Technology™**, the latest edition to VSY Biotechnology's IA-HA portfolio, we set a new benchmark in osteoarthritis treatment by introducing the world's first and only linear structured and simultaneously cross-linked sodium hyaluronate, leading to an enhanced therapeutic effect and long-lasting pain relief for patients worldwide.



The Reviscon® promise - Focus on the patient!

Our continuous investment in the research and development of disruptive therapies for the treatment of musculoskeletal diseases reflects VSY Biotechnology's approach of using meticulous scientific precision to tackle the spread of one of the most challenging health problems of our time - osteoarthritis of the joints!

Re-Cross by Reviscon® - clinically proven, effective, safe, and well tolerated by patients around the globe!

A clinically proven, symptom-oriented therapy is intra-articular injection with our hyaluronic acid preparation **Re-Cross by Reviscon®**. This treatment method has become an integral part of global physician's every day's clinical practice, with a clear focus on the patient.

A team of experts is at your disposal for further information.

Please contact us at orthopedics@vsybiotechnology.com or visit our website www.reviscon.net

Your VSY Biotechnology Orthopedics Team

OA therapy options with Re-Cross®

An intra-articular injection therapy with the cross-linked, viscoelastic sodium hyaluronate **Re-Cross by Reviscon®** is beneficial for patients:

1

suffering from joint pain due to osteoarthritis of the synovial joints (Kellgren – Lawrence Grade II-III).

2

directly post-operative, who underwent arthroscopic knee surgery and joint lavage [2].

3

with an active lifestyle, active and leisure athletes with first signs of movement limitations and joint pain.

4

who are seeking a clinically effective alternative to anti-inflammatory drugs and NSAID's.

5

who have shown to be allergic against biological impurities, animal proteins and/or preservative agents.

6

who suffer from osteoarthritic conditions due to obesity.



Re-Cross® features & benefits

The trailblazer in cross-linked single-shot OA therapy!

HXL HYBRID XLink Technology™



With a molecular weight of 1 Million Dalton (MDa) **Re-Cross®**, coupled with the meticulously designed **HXL HYBRID XLink Technology™**, **Re-Cross®** IA-HA is tailored for rest and physical activity, and aligns with the dynamic nature of joint movement. The cross-linked NaHa degrades slower than the linear NaHa, thereby providing unique cohesive energy characteristics, increased bioavailability, and thus prolonged pain relief.

Additionally, the combination of linear and cross-linked NaHa helps minimizing further cartilage damage and fosters a healthy joint environment by its anti-inflammatory effect.

Linear and cross-linked molecule structures



Re-Cross® 2.2% (88 mg) sodium hyaluronate (NaHa) is powered by VSY Biotechnology's proprietary **HXL HYBRID XLink Technology™**.


By administering a combination of the dispersive, linear, and cohesive, cross-linked NaHa molecule chains into the synovial joints, both, mechanical strength, and shock absorbing properties as well lubricating and joint cushioning efficacy are enhanced, especially in case of articular cartilage damage.


Highly purified NaHa solution



Re-Cross® 2.2% (88 mg) is a non-pyrogenic, non-immunogenic, highly purified, cross-linked sodium hyaluronate (NaHa) solution for intra-articular injections into the synovial joints that is meticulously crafted for precision and purity, catering to individuals seeking a targeted and refined approach to joint health.

Re-Cross® IA-HA is biotechnologically manufactured (microbiological fermentation) according to ISO 13485 and does not contain any preservatives or ingredients from biological sources.





Enhanced lubricating- and shock absorbing properties



Re-Cross® 2.2% (88 mg) sodium hyaluronate is a hyaluronic acid with 1 MDa, effectively enhancing shock absorption in the synovial joints. The mixed patterns of linear and cross-linked molecule chains in **Re-Cross®** provides both, a high lubricating layer on the surrounding cartilage and tissue as well as an increased shock absorption effect, supporting the weight bearing capacities of the affected synovial joints. Simultaneously, **Re-Cross®** diminishes friction, enhances joint mobility, and provides long term pain relief between 6 to 12 months.^[1]

Mimicking healthy human synovial fluid properties



Re-Cross® 2.2% (88 mg) is designed to imitate healthy, natural synovial fluid properties to the highest extent possible. The biological mimicry of **Re-Cross®** IA-HA ensures optimal bioavailability and integration into the joint environment, with minimal degradation, aligning closely with the natural properties of human synovial fluid. The technology behind **Re-Cross®** IA-HA is laid out for patients with early onset OA, and especially for individuals an active lifestyle, active and leisure athletes with first signs of movement limitations and joint pain.

Patient centric administration protocol



The **Re-Cross®** administration protocol of only one syringe every six to twelve months, offers a sustainable and convenient therapy solution for individuals seeking long-lasting joint support and underscores the product's efficacy in promoting joint health over an extended period. This approach reflects VSY Biotechnology's commitment to patient centric, well-structured, and effective treatment plans and optimizes the impact of IA-HA OA therapy, allowing for gradual and sustained improvement in joint health.

Patient safety and therapy efficacy



Intra-articular viscosupplementation into the synovial joints with **Re-Cross®** sodium hyaluronate is a safe and efficient procedure for patients suffering from OA and who have not responded sufficiently to previous pharmacologic treatments. To date, zero product related side-effects have been reported^[1].

Re-Cross® - powered by HXL HYBRID XLink Technology™

The one-shot IA-HA solution for long-lasting pain relief!

Re-Cross by Reviscon® is powered by VSY Biotechnology's unique and proprietary **HXL HYBRID XLink Technology™** allowing for a patient centric and dedicated one-shot viscosupplementation therapy every six to twelve months, thereby supporting shock absorption, diminishing friction between the joints, and thus leading to a long-lasting pain relief.



RE-CROSS®

Cross-Linked Sodium Hyaluronate for Intra-Articular Injections

by
Reviscon



Recross® at a glance!



Recross® by Reviscon®



Reviscon® Mono

API Active Pharmaceutical Ingredient	Cross-Linked Sodium Hyaluronate (NaHa)	Linear Sodium Hyaluronate (NaHa)
Viscosity	300.000 MPa	900.000 MPa
Molecular weight	1 MDa	3 MDa
Concentration	88 mg / 2.2 %	48 mg / 2.0 %
PH value	pH 6.8 – 7.6	pH 6.8 – 7.6
Osmolality	300 to 350 mOsm/kg (similar to the human body synovial fluid)	300 to 350 mOsm/kg (similar to the human body synovial fluid)
Volume	4.0 ml	2.4 ml
Origin	Biological Fermentation	Biological Fermentation
Injection intervals	Single Shot (every 6 - 12 months)	Single Shot (every 6 months)
Shelf-life	3 years	3 years
Reference number	700 001 15	700 000 54

1. Data on file (VSY Biotechnology GmbH, Leinfelden-Echterdingen, Germany)

2. Schneider S, Zahn T, Springorum HW, Schofer M. Influence of post-arthroscopic intra-articular administered hyaluronic acid on parameters of function and pain in the knee.OUP 2014; 7: 333–339 DOI 10.3238/oup.2014.0333–0339

Disclaimer

This document is intended exclusively for experts in the medical field, i.e. for physicians, and is expressly not for the information of laypersons. The information on the products and/or procedures contained in this document is of general nature and does not represent any medical advice or therapy recommendation. Since this information does not constitute any diagnostic or therapeutic statement regarding any individual medical case, individual examination and advising of the respective patient are necessary and not replaced by this document in whole or in part. Please refer to the instructions for use (IFU).

VSY Biotechnology GmbH

Esslinger Str. 7 D-70771 Leinfelden-Echterdingen

T: +49 711-997606-333

F: +49 711-997606-334

orthopedics@vsybiotechnology.com

Order here: customerservice@vsybiotechnology.com



www.reviscon.net